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Objective: The objective of the study is to determine the risk factors for groin recurrence
(GR) in patients with primary vulvar squamous cell carcinoma (SCC) after inguinofemoral
lymphadenectomy (IFL) without lymph node metastases and/or adjuvant chemoradiotherapy.
Methods: The study is a multicenter retrospective review of clinical and histopathological
data of patients with lymph nodeYnegative vulvar SCC who underwent an IFL. Patients with
and without GRs were compared to identify risk factors.
Results: In 134 patients, 252 groins were eligible for the analysesV16 patients underwent
ipsilateral IFL and 118 patients underwent bilateral IFL. Groin recurrences occurred in
4 (1.6%) of the 252 dissected groins. Besides, 1 patient who underwent ipsilateral IFL had a
recurrence in the nonoperated contralateral groin; this groin was left out of analysis. The
median number of dissected nodes per groin was 9.8 (range, 1Y38) in all patients and
6.5 (range, 5Y8) in patients with GR. Multivariate analyses showed that GR was related to
poor differentiation (P = 0.04), and node count less than 9 (P = 0.04), no association with
age, tumor localization, tumor diameter, focality, invasion depth, or stage was found.
Nineteen patients with both low node count and poor differentiation had 19% GRs.
Survival analyses showed less favorable survival in patients with poor differentiation.
Conclusions: The overall risk of developing GR after negative IFL in patients with vulvar
SCC is low (1.6% per groin) but significantly higher in patients with tumors with a poor
differentiation and lymph node count less than 9 at IFL. A large well-designed prospective
study is needed to evaluate closer surveillance in patients at risk.
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Inguinofemoral lymphadenectomy (IFL) plays a central rolein the surgical treatment of squamous cell carcinoma (SCC)
of the vulva as part of the staging procedure and to remove
metastatic disease.1 Surgical management of SCC of the
vulva is tailored; in tumors larger than 4 cm and in multifocal
tumors, an IFL is performed. In many European countries,
IFL is currently replaced by sentinel node (SN) procedure in
patients with unifocal lesions less than 4 cm because of the
low groin recurrence (GR) risk after negative SN and the
reduction of morbidity.2,3
Groin recurrences in previously dissected groins (without
lymph node metastases) infrequently occur with a reported
incidence of about 1.3% to 4.3%.4 Nevertheless, they carry a
very poor prognosis, with reported median survival of only
9 months.5 As a result, great efforts should be made at the
time of primary treatment to minimize the risk of GR, and it
may be advantageous to select patients that have a high risk
for GR after IFL.
It is suggested that the number of dissected lymph
nodes correlates with GRs. In 2010, a SEER analysis in
patients with node-negative SCC of the vulva showed that
overall survival (OS) and disease-free survival differed be-
tween patients with 10 or less versus patients with 11 or more
dissected lymph nodes; a hazards ratio of 1.5 (95% confidence
interval [CI], 1.16Y1.94) for OS and 1.71 (95% CI, 1.08Y2.71)
for disease-free survival was reported.6 However, from this
study, it is unclear whether lymph nodes were counted per
groin, where the recurrences were located, and what type of
primary surgery was performed. Butler et al4 published a
retrospective study of 139 patients (228 groins) with IFL for
SCC of the vulva. In 3 of the 89 patients who underwent a
bilateral IFL and in 3 of the 50 who underwent unilateral IFL,
a GR occurred. Based on these 6 GRs, a node count below
8was found to be a risk factor forGR (P= 0.03). However, the
3 GRs in the patients who underwent unilateral IFL were
located in the contralateral, undissected groin. It is not clear
if and how this affected the node count. Other studies in-
volve GR after superficial IFL only,7,8 a technique that is
currently abandoned in favor of complete (superficial plus
deep) IFL or SN assessment.1,9
We present a study that investigates whether there is
a minimal nodal count that can be considered to represent
an adequate IFL with a low rate of GRs. Furthermore, we
studied other tumor characteristics that may give increased
risk for GRs.
MATERIALS AND METHODS
A retrospective review of clinical and histopathological
data was performed of patients with primary SCC of the
vulvawho have been treated at 3 Dutch university hospitalsV
the Cancer Center at the Erasmus Medical Center in Rotterdam,
the AcademicMedical Center of Amsterdam, and the Radboud
University Medical Center in Nijmegen, the NetherlandsV
between January 2000 and December 2010. Patients underwent
ipsilateral IFL in lateralized and bilateral IFL in central
(medial margin G1 cm from midline) SCC of the vulva. In
patients with unilateral IFL, only GRs in the dissected groin
were analyzed. The uniform technique of complete IFL
was performed via separate incisions, and all lymph nodes
superficial to the inguinal ligament and lymph nodes under
the cribriform fascia were removed. The upper limit of the
dissection was 2 cm above the inguinal ligament to include
all the inguinal nodes. All subcutaneous tissues superficial to
Scarpa’s fascia were preserved to minimize skin necrosis. In
general, the saphenous vein was spared. The fascia lata
overlying the femoral blood vessels was opened, and the fatty
tissue containing the femoral lymph nodes was removed from
within the fossa ovalis.1
Patients with stage I and II vulvar cancer (FIGO 2009)10
who underwent IFL, had negative groin nodes, and did not
receive adjuvant chemoradiotherapy were included in the anal-
yses. Patients were identified through a national pathological
data base (PALGA). Clinical data included age, tumor locali-
zation, tumor diameter, and unifocality or multifocality. Path-
ological data included depth of invasion, grade, vascular space
invasion, tumor-free margin, and nodal disease. Pathologists
with special interest in gynecologic oncology examined the
specimen in a similar way in all institutions. Information on
the time and site of recurrences and the vital status were re-
trieved, and in case of death, the cause and date of death were
registered. The end point of this study was the first recurrence
in a groin that was clinically and pathologically confirmed.
Groin recurrence was defined as a recurrence located in the
anatomic site where the previous IFL took place; bridge re-
currences were not considered as GRs.
In 2009, the FIGO classification for SCC of the vulva
changed. To compare our data with existing literature, we
have used the FIGO (1988) classification in our analyses for
all patients.10,11
From 2000 onwards, the SN dissection was introduced
and practiced in the Netherlands in the setting of a clinical
trial; nearly all ‘‘low risk’’ patients (unifocal tumor e4 cm)
were included.2 As a result, most of the patients in our study
have either a tumor greater than 4 cm or multifocal disease.
Patients who declined to enter the SN trial, and patients in the
trial in whom SN detection was not possible because of
technical failure, underwent an IFL and were included in our
study as well.
Statistical analyses were performed using SPSS version
20.0. The risk factors of recurrence were tabulated, and de-
scriptive statistics and histograms were used to summarize
empirical distributions of negative node counts by GR status.
Statistical significance of association between risk factors
and GR status were assessed by Fisher exact test and Pearson
W2 test. The multivariate analysis was conducted using back-
wards logistic regression and the survival analyses by Kaplan-
Meier analyses. In the multivariate analysis, we used a model
with all parameters with a P value of 0.20 or less in the uni-
variate analysis. A P value of less than 0.05 was considered
to be significant.
According to Dutch law on ethics and research, ret-
rospective research that does not involve administration of
study medication or interventions are exempted from obtain-
ing permission from an ethical committee.
RESULTS
In the study period (2000Y2010), 134 patients with
primary SCC of the vulva met our inclusion criteria; 4 patients
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had GRs and 130 patients had not. One patient had a recur-
rence in a contralateral, not dissected groin, so this groin was
left out of the analysis. Patient characteristics are displayed
in Table 1. Age at diagnosis ranged from 27 to 95 years (mean,
68.6 years) and follow-up duration from 1 to 145 months
(mean, 44.0 months). The 4 patients with lymph node recur-
rence had additional imaging to discover concomitant meta-
static disease; in 2 of the 4 patients, positive pelvic lymph
nodes were discovered.
A total number of 252 groins were dissected in 134 pa-
tients (118 bilateral and 16 unilateral) with a wide variation
in the number of negative nodes collected per groin ranging
from 1 to 38 (mean [SD], 9.8 [4.7]; median, 9.0) (Fig. 1).
Node count less than 9 was present in 112 (44.4%) of the
252 IFLs.
Four patients (1.6%) had a unilateral GR in the 252
previously dissected groins. The number of negative nodes
dissected in patients with GR ranged from 5 to 8 (2 patients
had 5 and 2 patients had 8 nodes dissected; mean [SD], 6.5 [1.7]).
In patients with GR, a significantly lower number of nodes
(P = 0.038) were dissected in comparison with patients that
did not have a GR. All GRs occurred between 5 and 17months
(mean, 12.5 months). Of the 4 patients with GR, 3 died of
disease and one is still alive (follow-up time, 57 months) with-
out evidence of disease.
A univariate analysis was conducted including clinical
and histopathological parameters of 252 IFLs (Table 2). A
node count less than 9 (P = 0.038) and a poor differentiation
(P = 0.038) were significantly related to GR. All other para-
meters such as age, diameter, depth of invasion, or focality
were not significantly different between patients with or with-
out a GR.
In the multivariate analysis, the 3 univariate risk factors
for GR with a P G 0.20 were included. Both node count less
than 9 and differentiation grade were significant (P G 0.05)
whereas invasion depth was not (P = 0.48).
Of the 52 patients with a poorly differentiated tumor,
GR occurred in 3 (5.7%). When both risk factors (poor
differentiation grade and node count G9) were present, GR
occurred evenmore frequent, in 3 (19%) of 16 groins (P = 0.025).
The Kaplan-Meier survival curves showed that the
disease-specific survival (DSS) was similar in the group with
node count less than 9 and node count 9 or more (Fig. 2). The
DSS was shorter in the group with poor differentiation
compared with well and moderately differentiated tumors
TABLE 1. Patient characteristics of 134 patients with SCC of the vulva and negative IFL
No GR (n = 130) GR (n = 4)
Age, mean (SD), y 68.8 (13.6); range, 27Y95 62.8 (18.2); range, 38Y78
Diameter of vulvar tumor, mean (SD), mm 35.4 (18.6); range, 7Y90 39.3 (14.1); range, 25Y47
Tumor e20 mm, n 36 0
Tumor 920 mm, n 94 4
Depth of invasion, mm 7.3; range, 0.7Y35 7.5; range, 3Y15
Multifocal tumor, n 35 2
Unifocal tumor, n 95 2
Follow-up, mean (SD), mo 44.6 (33.2); range, 1Y145 25.8 (21.0); range, 12Y35
Lost to follow-up 0 0
Local recurrence 25 (19.2%); 1 skin bridge (0.8%) 0
Death of disease 10 (7.7%) 3 (75%)
Local recurrence 5
Skin bridge 1
Pelvic recurrence 2
Distant recurrences 2
GR N/A 3
Death of other causes 20 (15.3%) 0
FIGURE 1. Histograph of the number of lymph nodes
removed in 252 groins in 134 patients with SCC of
the vulva. The red dots represent groins with GR.
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(Fig. 3). Figure 4 displays the DSS of patients with poorly
differentiated tumors with a node count 9 or more and less
than 9, and the latter had a poorer DSS.
DISCUSSION
Groin recurrence is a rare but often fatal complication
in SCC of the vulva. In this study, we conclude that in Tany
N0 M0 vulvar tumor, a node count less than 9 lymph nodes
and poor differentiation of the tumor are risk factors for
GR in SCC of the vulva in previously dissected groins.
An isolated GR in a groin with negative lymph nodes
after inguinofemoral lymph node dissection can theoretically
be caused by either remaining nodal tissue, which could be
considered as inadequate surgery or histopathology at which
micrometastasis in nodes where not resected, or in transit
metastases in afferent lymph channels that can hardly be in-
fluenced by more radical surgery. Our study involved patients
who underwent complete groin dissection. A recurrence rate
TABLE 2. Univariate analysis of 252 dissected groins
No GR (n = 248) GR (n = 4) P
Node count G9 108 4 0.038
Largest diameter, mean (SD) 35.4 (18.6); range, 7Y90 39.3 (14.1); range, 25Y47 0.54
Focality 0.30
Unifocal 180 2
Multifocal 66 2
Missing 2
FIGO (1988) stage 1.00
GT2 78 1
T2 138 3
9T2 32
Localization tumor 0.41
Central 168 2
Lateral 74 2
Missing 6
Surgical margin tumor, mm 0.65
G8 mm 76 2
Q8 mm 149 2
No margin 7
Missing 16
Depth of invasion, mean (SD), mm 7.5 (6.3); range, 1Y35 12.0 (8.0); range, 3Y21 0.19
LVSI 1.00
No 84 2
Yes 17 0
Missing 149 2
Differentiation grade 0.038
Well 82 0
Moderate 113 1
Poor 49 3
Missing 4
FIGURE 2. Disease-specific survival for patients with
node count less than 9 and 9 or more lymph
nodes per groin (P = 0.40).
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of 1.6% per groin was found, which is similar to the 1.3%GR
reported by Butler et al.4 Both are in contrast to a review on
superficial IFL where a recurrence rate of 5.3% (95% CI,
3.2%Y8.2%) was found.7 This confirms the importance of
performing a complete IFL in SCC of the vulva.
The mean number of lymph nodes dissected in our study
was 9.8, slightly higher than in the study of Butler et al4
(mean, 8.7). A major drawback of the study of Butler et al4
is that 3 of the 6 GRs occurred in the contralateral non-
dissected groin, and therefore, this does not reflect a pos-
sible inadequacy of the surgical technique. A large variation
of the number of resected nodes was observed in our study,
with the 25 and 75 percentiles at 7 and 12 nodes. Overall
survival was independent of the number of removed nodes.
Therefore, the conclusion of an ‘‘adequate’’ node dissection
cannot bemade based on the number of nodes removed, so the
surgical limitations should be leading in this respect. This is
in contrast with the epidemiological SEER study,6 in which
the authors concluded that the removal of more than 10 nodes
was associated with a significantly higher OS. Moreover,
the SEER study was different from ours in primary out-
come, namely, OS versus GRs. Substantial information about
adjuvant treatment, number of recurrences, site of recur-
rences, and the number of nodes per groin were missing in
the SEER publication.
In the present study, no patients with a node count of
9 or more did have a GR. It should be noted that in only
140 (56%) of the 252 of the groins, 9 or more nodes were re-
moved. Butler et al4 reported no GR in groins with a node count
of 8 or greater. Both results are in the same (clinical) range.
A second identified risk factor for GR was a poor
differentiation of the tumor; in 3 (5.8%) of the 52 groins with
poor differentiation, a GR occurred (P = 0.038). These data
are in line with the study of Butler et al4; they found 1 (2.2%)
of 46GR inwell-differentiated tumors comparedwith 5 (5.4%)
of 93 in moderately/poorly differentiated tumors (P = 0.66).
We found that when both risk factors (node count G9 and
poor differentiation) were present, the incidence of GR was
the highest (19%).
A concern raised is that in 1 (6.3%) of 16 patients
developed a GR in the contralateral, undissected groin after
ipsilateral IFL. This is in concordance with Butler et al4, who
reported 3 contralateral recurrences (6.0%) of 50 undissected
groins after ipsilateral IFL. This percentage is much higher
than reported previously.9,12,13 The first studies on ipsilateral
IFL showed that recurrence rate was low (G1%) in patients
with lateralized (91 cm from midline), unifocal tumors less
than or equal to 2 cm without ipsilateral metastasis located
posterior from the clitoris,9,12 whereas a later published study
showed a risk of recurrence after ipsilateral IFL of 2.5%13
The recommendation to perform only an ipsilateral lymph
node dissection in lateralized tumors in which the ipsilateral
groin nodes are negative is based on these studies.9,12,13 A
recent publication of the GOG 173 group showed a signif-
icant reduction in drainage of vulvar cancer to the contra-
lateral groin when the tumor was more lateralizedV70% of
midline tumors, 58% of lateral/ambiguous tumors, and 22%
of lateral tumors drained to the contralateral groin.14 The
6% contralateral recurrences that were reported in our study
and in the study of Butler et al4 can be due to a sliding scale;
more patients underwent ipsilateral IFL who did not strictly
fulfill the original stringent criteria of a unifocal lateral
small (diameter, e2 cm) tumor dorsal of the clitoris.
The analysis of the role of lymphovascular space in-
vasion (LVSI) was not possible because of the missing data in
about 60% of our patients. In previous studies, the role of
LVSI on OS were inconclusive; 2 studies showed reduced
OS,15,16 whereas in another study, the presence of LVSI was
not significantly associated with a shorter OS.17 In the study
of Butler et al,4 there was only a trend in association between
LVSI and GR (P = 0.08).4
Both the retrospective design and the lack of central
pathology review are weak points of our study. Until now, no
prospective studies about risk factors for GRs are available
most likely because of the low incidence of both SCC of the
vulva and GR after deep and superficial dissection. Although
a central pathology review was not performed, all specimens
were examined by dedicated gynecological pathologists in
FIGURE 3. Disease-specific survival for patients
according to differentiation grade (P = 0.03).
FIGURE 4. Disease-specific survival for patients with
poorly differentiated tumors in relation to node
count (P = 0.025).
International Journal of Gynecological Cancer & Volume 24, Number 4, May 2014 Node Count in Vulvar Cancer
* 2014 IGCS and ESGO 777
Copyright © 2014 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
university cancer centers according a standardized protocol.
It is generally assumed that the number of lymph nodes
found is related to the efforts of the pathologists,18 but proof
is lacking.
Three of 4 patients with GR died. Kaplan-Meier sur-
vival analyses showed that poor differentiation of the primary
tumor decreased the 5-year DSS although node count less than
9 lymph nodes did not. This may be due to the high incidence
of node count less than 9 (44%) in relation to the relative low
incidence of GR (1.3%). Disease-specific survival was lower
in poorly differentiated tumors with a node count less than
9 than in a node count 9 or more.
In conclusion, the risk of developing an isolated GR
after a negative IFL in patients with vulvar SCC is low (1.6%
per dissected groin). A significant relation between a node
count less than 9 (P = 0.038) and/or poorly differentiated tumor
(P = 0.038) with isolated GRs was found. A combination of
both risk factors was present in 3 of 4 patients with GRs. A
properly performed complete inguinofemoral lymph node dis-
section is warranted to avoid remaining nodal tissue poten-
tially harboring metastatic foci. A strict selection of patients
for ipsilateral or bilateral groin dissection is important to
prevent GR in the contralateral undissected groin. For current
practice, we would not yet like to suggest adjuvant treatment
in the high risk group. Further studies are needed to confirm
these findings and to define patients who can benefit from
adjuvant treatment.
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